Nivolumab plus relatlimab in patients with previously untreated advanced melanoma (RELATIVITY-047)
Source: View publication →
The RELATIVITY-047 trial demonstrated that the combination of the anti-LAG-3 antibody relatlimab and the anti-PD-1 antibody nivolumab significantly improves progression-free survival compared to nivolumab monotherapy in patients with previously untreated advanced melanoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial established the first regulatory approval for a LAG-3 blocking antibody, introducing a new standard-of-care combination that provides an alternative to more toxic dual-checkpoint regimens while demonstrating superior efficacy to PD-1 monotherapy.
Historical Context
The treatment of advanced melanoma was revolutionized by PD-1 blockade (nivolumab, pembrolizumab) and dual PD-1/CTLA-4 blockade (nivolumab/ipilimumab). However, dual therapy, while highly effective, is associated with significant immune-related toxicity. The RELATIVITY-047 trial aimed to leverage the LAG-3 pathway—an inhibitory receptor distinct from CTLA-4—to enhance anti-tumor immunity with a potentially better safety-to-efficacy ratio.
Guided Discussion
High-yield insights from every perspective
What is the biological mechanism of LAG-3, and why does combining its blockade with PD-1 inhibition theoretically enhance the anti-tumor immune response compared to PD-1 blockade alone?
Key Response
LAG-3 (Lymphocyte-activation gene 3) is a cell-surface inhibitory receptor found on T-cells that contributes to T-cell exhaustion. It binds to MHC class II molecules with higher affinity than CD4, thereby inhibiting T-cell activation and cytokine production. Since LAG-3 and PD-1 utilize distinct signaling pathways to suppress T-cell function, dual blockade provides a synergistic effect by simultaneously releasing two different 'brakes' on the immune system, more effectively restoring the effector function of exhausted tumor-infiltrating lymphocytes.
Based on the RELATIVITY-047 data, how does the safety profile of the nivolumab plus relatlimab fixed-dose combination compare to the established nivolumab plus ipilimumab regimen for untreated advanced melanoma?
Key Response
In RELATIVITY-047, Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 18.9% of the nivolumab-relatlimab group. This is notably lower than the historical Grade 3/4 TRAE rates for the nivolumab-ipilimumab combination (e.g., approximately 59% in CheckMate 067). This suggests that nivolumab-relatlimab offers a significantly more tolerable dual-checkpoint inhibition strategy, potentially reducing the need for high-dose corticosteroids and frequent treatment interruptions.
The RELATIVITY-047 trial demonstrated a PFS benefit across subgroups, but LAG-3 expression was evaluated using a 1% cutoff. Should LAG-3 expression levels be used as a predictive biomarker to select patients for this combination therapy in clinical practice?
Key Response
While the median PFS was longer in patients with LAG-3 expression >=1% (12.6 months) compared to <1% (4.8 months), the combination still outperformed nivolumab monotherapy in both groups. Because a benefit was observed regardless of expression status, LAG-3 IHC is not currently considered a necessary gatekeeper biomarker for treatment, mirroring the clinical application of PD-L1 in many melanoma settings.
In the absence of a head-to-head trial between nivolumab/relatlimab and nivolumab/ipilimumab, which clinical factors would lead you to prioritize the RELATIVITY-047 regimen as first-line therapy over the CheckMate 067 regimen?
Key Response
Clinicians often favor nivolumab/relatlimab for patients with a lower disease burden, asymptomatic status, or those at high risk for autoimmune complications, due to its superior safety profile. Conversely, for patients with high LDH, rapidly progressive visceral disease, or known brain metastases, nivolumab/ipilimumab (dose-dense 3mg/kg ipilimumab) remains the preferred standard due to more robust long-term overall survival and intracranial response data, despite its higher toxicity.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
RELATIVITY-047 utilized a fixed-dose combination (FDC). What are the pharmacological and clinical trial design advantages of using an FDC in this context, and how might this affect the interpretation of the dose-response relationship for relatlimab?
Key Response
FDCs ensure synchronized administration, reducing the potential for dosing errors and improving patient convenience. Methodologically, it simplifies the trial by treating the combination as a single agent. However, FDCs can obscure the individual dose-response contribution of the newer agent (relatlimab) and limit the ability to de-escalate or adjust the dose of one component in response to specific toxicities, necessitating rigorous Phase I/II dose-finding studies prior to the Phase III FDC implementation.
The median PFS for the nivolumab monotherapy arm in RELATIVITY-047 was 4.6 months, which is lower than the 6.9 months reported in CheckMate 067. Does this discrepancy suggest a higher-risk patient population or potential enrollment bias that could inflate the perceived hazard ratio of the combination?
Key Response
A seasoned reviewer would flag this discrepancy. Possible explanations include differences in the prevalence of poor prognostic factors (e.g., LDH levels, M1c/M1d stage) or the impact of prior adjuvant therapies (like anti-PD-1 or BRAF/MEK inhibitors) which were not present in earlier trials. If the control arm performs worse than historical benchmarks, the experimental arm's relative benefit (Hazard Ratio) may appear more significant, requiring careful cross-trial demographic comparison to ensure generalizability.
Given that RELATIVITY-047 met its primary endpoint of PFS but the OS data remained immature at the time of initial publication, how should current NCCN or ESMO guidelines weigh this evidence against established Category 1 recommendations for nivolumab/ipilimumab?
Key Response
Guidelines (like NCCN) have already added nivolumab/relatlimab as a 'Preferred' Category 1 option. However, the committee must decide if it is truly 'equivalent' to nivolumab/ipilimumab. In the absence of mature OS data and a direct head-to-head comparison, the recommendation often emphasizes the 'intermediate' position of this regimen—offering more efficacy than monotherapy with less toxicity than the ipilimumab combo, but noting the lack of long-term (5-year+) survival data that supports the older dual-blockade standard.
Clinical Landscape
Noteworthy Related Trials
CheckMate 066 Trial
Tested
Nivolumab
Population
Patients with previously untreated BRAF-wild-type advanced melanoma
Comparator
Dacarbazine
Endpoint
Overall survival
CheckMate 067 Trial
Tested
Nivolumab plus ipilimumab
Population
Patients with previously untreated advanced melanoma
Comparator
Nivolumab alone or ipilimumab alone
Endpoint
Progression-free survival and overall survival
KEYNOTE-006 Trial
Tested
Pembrolizumab
Population
Patients with advanced melanoma
Comparator
Ipilimumab
Endpoint
Progression-free survival and overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis